Sanofi (SNY) stock slips as the company's asthma therapy amlitelimab fails in a Phase 2 trial, despite its plans to evaluate ...

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients with heterogeneous inflammatory asthma. This would “potentially represent ...

Sanofi’s next-generation experimental asthma drug failed to significantly reduce flare-ups in patients with moderate-to-severe asthma, dimming hopes it could help offset the patent expiry of its ...

China announced on Friday that it would raise its levies on imports of U.S. goods to 125%, hitting back at U.S. President Donald Trump's decision to single out the world's second-largest economy for ...

The French pharmaceutical major has reportedly slashed the asking price for Lantus from an initial Rs 3,000 crore to Rs 2,000 crore, in a bid to draw more interest.